Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference

FORT WASHINGTON, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. VTAE, a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2016 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2016 at 1:10 p.m. EDT at the Westin Boston Waterfront.

A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A replay of the webcast will be archived on Vitae's website for 90 days following the presentation.

About Vitae Pharmaceuticals

Vitae Pharmaceuticals is a clinical-stage biotechnology company developing first-in-class product candidates with potential to transform the treatment paradigm for patients with significant unmet medical needs. Initial indications being pursued include psoriasis, other autoimmune disorders, and atopic dermatitis. Vitae's lead clinical assets include VTP-43742, an oral RORyt inhibitor currently being studied in patients with moderate to severe psoriasis, VTP-45489, a second and chemically distinct RORyt inhibitor being studied for its potential in autoimmune disorders, and VTP-38543, an LXRβ selective agonist being studied in patients with mild to moderate atopic dermatitis.

For additional information, please visit the company's website at www.vitaepharma.com.